View Older Stories View More Recent Stories
-
Baird Starts Tempus AI Inc (TEM) at Outperform
-
Tempus AI test outperforms standard biomarkers in predicting immunotherapy
-
Tempus launches AI-powered biomarker prediction tool Paige Predict
-
Northwestern Medicine partners with Tempus to expand cancer genomic testing
-
Tempus AI (TEM) call put ratio 1.1 calls to 1 put into updated guidance
-
Tempus AI reports preliminary 2025 revenue of $1.27 billion, up 83%
-
Tempus AI reports record contract value exceeding $1.1 billion
-
Tempus presents eight research abstracts at ASCO GI symposium
-
TD Cowen Reiterates Hold Rating on Tempus AI Inc (TEM)
-
Tempus AI Inc (TEM) PT Raised to $105 at BTIG
-
Tempus partners with IFLI on follicular lymphoma research study
-
Tempus AI Inc (TEM) PT Lowered to $95 at Canaccord Genuity
-
Tempus AI, Inc (TEM) Reports Q3 Loss of $0.11, Offers Guidance
-
Tempus AI (TEM) call put ratio 2.9 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 1.4 calls to 1 put into quarter results
-
Tempus AI valuation catches up with its growth, says TD Cowen downgrading stock
-
TD Cowen Downgrades Tempus AI Inc (TEM) to Hold
-
Canaccord Genuity Reiterates Buy Rating on Tempus AI Inc (TEM)
-
Tempus partners with Whitehawk Therapeutics for cancer research
-
Ambry Genetics enhances breast cancer risk assessment tool with breast density
-
Tempus AI Inc (TEM) PT Raised to $95 at Guggenheim
-
Renalytix partners with Tempus AI to expand kidney disease testing
-
Tempus AI Inc (TEM) PT Raised to $98 at H.C. Wainwright
-
Tempus receives FDA clearance for updated cardiac imaging device
-
Stifel on Tempus AI Inc (TEM): 'we struggle to find upside to the current valuation'
-
H.C. Wainwright Starts Tempus AI Inc (TEM) at Buy
-
Tempus acquires digital pathology AI company Paige for $81.25 million
-
Tempus AI Inc (TEM) PT Raised to $85 at BTIG
-
Tempus AI director files to sell $3.1 million in stock
-
Tempus AI Inc (TEM) PT Raised to $72 at TD Cowen
-
Tempus AI (TEM) Files Mixed Shelf
-
Tempus AI, Inc (TEM) Tops Q2 EPS by 3c
-
Tempus AI, Inc (TEM) Reports Q2 Loss of $0.22, provides guidance
-
Tempus AI (TEM) call put ratio 1.6 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 2.1 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 1.8 calls to 1 put quarter results
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Tempus receives FDA clearance for heart condition detection software
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
Personalis extends Tempus partnership to include colorectal cancer testing
-
Tempus AI expands care pathway platform to breast cancer
-
TEM INVESTOR NOTICE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
-
Tempus AI (TEM) Announces Proposed $400M Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

